On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported second-quarter adjusted EPS of $11.56, up 13% year-over-year, beating the consensus of $10.61. The company reported sales of $3.55 billion, up 12%, beating the consensus of $3.38 billion. Also Read: Europe Approves Sanofi/Regeneron’s Dupixent for ‘Smoker’s Lungs’ A Month After US FDA Asks For Data. “Regeneron had a strong quarter, with total revenue up 12% driven by notable growth for EYLEA HD, Dupixent, and Libtayo,” said Leonard S. Schleifer, Board co-Chair, President and